A new inter partes review filed at the Patent Trial and Appeal Board could be one to watch for companies operating at the intersection of life sciences, nutraceuticals, and consumer health. In IPR2026-00400, the proceeding is captioned Thorne Research, Inc. and was filed on June 22, 2026.

At this early stage, the PTAB docket signals that a patent challenge involving Thorne Research is underway, but practitioners should note that key details—including the specific patent claims at issue, the identity of the petitioner and patent owner as reflected in the styled papers, and the precise invalidity combinations asserted—may develop as the record fills out. That is often where the strategic significance of a case becomes clear: the petition, preliminary response, and any institution decision will frame both the scope of the challenge and the Board’s appetite for the asserted theories.

What is already clear is why this filing matters. Thorne Research is a well-known name in the health and wellness space, and PTAB disputes involving companies in that sector can raise recurring issues around formulation claims, method-of-treatment claims, ingredient combinations, and obviousness arguments built from scientific and commercial literature. Depending on the patent ultimately challenged here, counsel may see disputes over whether prior art teaches motivation to combine known compounds, whether secondary considerations can carry weight in a crowded field, or whether the claims are vulnerable under anticipation or obviousness grounds supported by patents, printed publications, or both.

For patent practitioners, this case is worth following for another reason: PTAB proceedings often become a pressure point in parallel enforcement or licensing campaigns. Even before institution, an IPR can affect settlement posture, district court scheduling, and valuation of a portfolio. For in-house IP counsel, especially those managing consumer health or supplement-related assets, the case may offer useful insight into how challengers are framing prior-art attacks against product and formulation patents in a competitive market.

As the docket develops, the most important documents to watch will be the petition itself, any patent owner preliminary response, and the Board’s institution decision. Those filings should reveal the challenged patent, the parties, and the exact statutory grounds for review under 35 U.S.C. §§ 102 and/or 103, along with the prior art references being used to support the attack.

View full case on Docket Alarm